Stockwinners Market Radar for November 29, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:23 EST DraftKings General Counsel Stanton Dodge sells $4.7M in common stock - In a regulatory filing, DraftKings disclosed that its General Counsel Stanton Dodge sold 123.6K shares of common stock on November 29th in a total transaction size of $4.7M.

20:21 EST Cathie Wood's ARK Investment bought 200K shares of SoFi Technologies today

20:20 EST Cathie Wood's ARK Investment bought 222K shares of Robinhood

19:58 EST Vista Outdoor rejects unsolicited proposal from Colt CZ - Vista Outdoor "announced that its Board of Directors, following consultation with its financial and legal advisors, has rejected the unsolicited proposal received on November 22, 2023 from Colt CZ Group SE to combine Colt CZ and Vista Outdoor. The Vista Outdoor Board continues to recommend the acquisition of the Sporting Products business by Czechoslovak Group a.s. and remains committed to acting in the best interests of Vista Outdoor stockholders. The acquisition of the Sporting Products business by CSG is expected to close in calendar year 2024, subject to approval of Vista Outdoor's stockholders, receipt of necessary regulatory approvals and other customary closing conditions."

19:50 EST LQR House Inc trading halted, news pending

19:27 EST Tetra Tech CEO sells $3.55M in common stock - In a regulatory filing, Tetra Tech disclosed that its CEO Dan Batrack sold 22K shares of common stock on November 28th in a total transaction size of $3.55M.

18:35 EST Astellas Pharma's fezolinetant shows efficacy in Phase 3b VMS trial - Astellas Pharma will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms - VMS - associated with menopause in women considered unsuitable for hormone therapy, at the 15th Congress of the European Society of Gynecology in Amsterdam. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. The study of more than 450 women considered unsuitable for hormone therapy met all primary and secondary endpoints at 24 weeks. For the primary endpoint of mean change from baseline in the frequency of moderate to severe VMS, fezolinetant 45 mg demonstrated a statistically significant reduction of -1.93 vs. placebo. For the key secondary endpoint of mean change from baseline in the severity of moderate to severe VMS, fezolinetant 45 mg demonstrated a statistically significant reduction of -0.39 vs. placebo. For the secondary endpoint of mean change from baseline in patient-reported sleep disturbance, fezolinetant 45 mg demonstrated a statistically significant reduction of -2.5 vs. placebo. Treatment-emergent adverse events were reported by 65% of patients in the fezolinetant group vs. 61% in the placebo group. The most common TEAEs were COVID-19, headache and fatigue.

18:16 EST Veralto shareholders reject mini-tender offer by TRC Capital - Veralto "has become aware of an unsolicited "mini-tender offer" made by TRC Capital Investment Corporation to Veralto shareholders to purchase up to 2,000,000 shares of Veralto common stock at a price of $65.40 per share. TRC's offer price represents a discount of $2.96 per share, or 4.33 percent, below Veralto's closing price of $68.36 on October 30, 2023, the last trading day prior to the announcement of TRC's offer. The closing price of Veralto's common stock on November 28, 2023 was $73.32 per share. Veralto recommends that shareholders reject TRC's unsolicited offer because, among other reasons, the offer price is below Veralto's current share price. The offer is also subject to numerous conditions. Veralto also recommends that any shareholders who have tendered shares to TRC withdraw those shares by providing the written notice described in the offering documentation before the expiration of the offer, which is currently scheduled for 12:01 a.m., New York City Time, on November 30, 2023, subject to extension at TRC's discretion."

18:08 EST Atara Biotherapeutics to present 'positive' tab-cel data during ESMO session - Atara Biotherapeutics announced positive new data for tabelecleucel in patients with relapsed or refractory or treatment-naive Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system following solid organ transplant or hematopoietic cell transplant. These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland. The clinical experience from this combined analysis of four single-arm, open-label studies, including the multicohort Phase 2 EBVision trial expands on previous data from two single-center, Phase 2 studies, and multicenter, expanded-access protocol. "EBV+ CNS PTLD is a rare but extremely serious disease, and patients often face a poor prognosis that underscores the urgent medical need," said AJ Joshi, M.D., Executive Vice President, Chief Medical Officer at Atara. "We're pleased to share new multicenter data, including the first results from our ongoing multicohort EBVision trial and first clinical trial report of treatment with tab-cel in the first line setting. Tab-cel shows a strong objective response rate in these high-risk patients with a favorable safety profile for patients with EBV-driven diseases."

17:58 EST Walmart Director Robson Walton sells almost $120M in company shares - Director and Beneficial Owner of Walmart Robson Walton disclosed the sale of 766,600 shares of company stock at $156.43 per share between November 27 and November 29 for a total transaction amount of $119,921,691.

17:50 EST Riot Games announces co-founder Marc Merrill named Chief Product Officer - Riot Games announced that Riot's co-Founder and former Co-CEO Marc Merrill will oversee the ecosystems of all products at Riot Games in the newly established role of Chief Product Officer,CPO. As CPO, Marc will lead the vision for the ecosystems surrounding each game while helping solidify the future paths of League, VALORANT, Teamfight Tactics, Wild Rift, Legends of Runeterra, and Research and Development at Riot. Reporting to CEO Dylan Jadeja, he will once again be responsible for aligning the broader product strategy and ensuring that gameplay, esports, and entertainment experiences across all titles are aligned to drive the most impactful and resonant outcomes for players. "In this next chapter for Riot, our goal is to double-down on our mission for players and to continue our evolution from delivering games as a service to bringing games as an experience to players," said Jadeja. "Marc is incredibly well suited to drive this improved orientation and focus on behalf of players. He helped build this place from the ground up, and he's been hands-on in making our mission a reality for years. He cares deeply about who we are and what we mean to players and has a nuanced understanding of what resonates across our products. Most importantly, Marc shares our strategic vision to unify games, esports, and entertainment into an experience for players that transcends the sum of their parts. We wouldn't be the Company we are today without his leadership, and I am honored and excited to have him step into this critical role." Reference Link

17:42 EST Ocean Biomedical receives Nasdaq notice over late filing - Ocean Biomedical announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market LLC stating that because the company has not yet filed its quarterly report on Form 10-Q for the period ended September 30, 2023, the company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.

17:39 EST AppLovin Chairman Foroughi sells almost $26M in company shares - The Chairman of Applovin, Adam Foroughi, disclosed the sale of 653,619 shares of company stock at $39.15 per share between November 27 and November 28, for a total transaction amount of $25,591,798.

17:30 EST Timber Pharmaceuticals delisting from NYSE to begin trading on OTC - Timber Pharmaceuticals announced that the staff of NYSE Regulation has determined to immediately suspend trading in the company's common stock from NYSE American as a result of the voluntary bankruptcy petitions filed under Chapter 11 by the company and certain of its subsidiaries on November 17. Trading of the company's common stock was suspended at the opening of business on November 29. Also on November 29, a Form 25-NSE was filed with the SEC, which will remove the company's securities from listing and registration on the NYSE American. Once the delisting from the NYSE American takes effect, the company's common stock is expected to begin trading on the OTC market expected to trade under the symbol "TMBRQ".

17:04 EST La-Z-Boy increases quarterly dividend 10% to 20c per share - La-Z-Boy declared a quarterly cash dividend of 20c per share on the common stock of the company, a 10% increase over the previous dividend. The dividend will be paid on December 18 to shareholders of record on December 11.

16:44 EST Roblox investor Han Kim sells $3.88M in common stock - In a regulatory filing, Roblox disclosed that its shareholder Han Kim sold 100K shares of common stock on November 27th in a total transaction size of $3.88M.

16:41 EST Discover to explore sale of Discover Student Loans portfolio - Discover Financial Services announced that the company's Board of Directors has authorized Discover management to explore the sale of the Discover Student Loans portfolio and the transfer of servicing of these loans to a third-party provider as it pursues strategic alternatives for the Discover Student Loans business. Additionally, Discover will stop accepting new applications for student loans February 1, 2024. There is no impact to current Discover Student Loans customers or their loans or payments at this time. "Discover's Board regularly reviews the strategic fit of all of our businesses, with a focus on providing exceptional customer service and allocating resources to optimize returns," said John Owen, Discover's interim CEO and President. "During a recent review, the Board determined that exploring the sale and transfer of servicing of Discover's student loans is aligned with those priorities, better enabling Discover to focus on our core banking products, capitalize on our growth opportunities and deliver long-term shareholder value. We are committed to a path forward that enables a seamless transition for our customers as they advance their education and financial goals."

16:37 EST Adial Pharmaceuticals receives noncompliance notification from Nasdaq - Adial Pharmaceuticals announced that it received notice from Nasdaq that the company has regained compliance with Nasdaq Listing Rule 5550, which requires listed companies to maintain stockholders' equity of at least $2.5M. Nasdaq will continue to monitor the company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report the company does not evidence compliance, it may be subject to delisting.

16:35 EST Wunong Net Technology receives noncompliance notification from Nasdaq - Meiwu Technology announced that it received a staff determination letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company of the determination from Nasdaq staff to delist the company's securities from The Nasdaq Stock Market, because, as of November 22, the company's securities had a closing bid price of 10c or less for ten consecutive trading days. Accordingly, the company is subject to the provisions contemplated under Listing Rule 5810.

16:34 EST Disney names Morgan Stanley's James Gorman as one of new board directors - The Walt Disney Company (DIS) Board of Directors has appointed James P. Gorman, Chairman and Chief Executive Officer of Morgan Stanley (MS), and Sir Jeremy Darroch, a veteran media executive and former Group Chief Executive of Sky, as new directors. Darroch's appointment is effective January 9, 2024, and Gorman's is effective February 5, 2024. The company states: "The selection of Gorman, a deeply respected leader at one of the world's preeminent global financial institutions, and Darroch, an accomplished chief executive and financial leader with significant experience in the international media and consumer products sectors, follows a lengthy and comprehensive search that began in April 2023. Their appointments reflect Disney's commitment to a strong board focused on the long-term performance of the company, strategic growth initiatives, the succession planning process, and increasing shareholder value. Gorman and Darroch will be included in the company's slate of director nominees in the proxy statement for Disney's 2024 Annual Meeting of Shareholders. Disney board member Francis A. deSouza has decided not to stand for reelection at the annual meeting, as he pursues new opportunities in the technology sector that will require his full attention. "

16:31 EST FOXO Technologies discloses NYSE notice regarding late filing of 10-Q - FOXO Technologies announced that on November 21, 2023, it received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide. The non-compliance results from the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 by the filing due date of November 20, 2023.

16:29 EST Snowflake jumps 7% to $187.60 after Q3 earnings beat, FY24 product revenue raise

16:28 EST Victoria's Secret reports Q3 comparable sales down 7% - CEO Martin Waters commented on the third quarter, "We delivered third quarter results within our guidance range, and we are encouraged by the improving sales trend as we transition into the all-important holiday season. Our sales trend in North America continued to improve as planned each month throughout the third quarter with October being our strongest month. Our teams have been resiliently focused on what is within our control and working tirelessly on multiple growth initiatives designed to create momentum. We are delivering key initiatives such as our new multi-tender loyalty program, new customer experience enhancements in our digital business, product improvements and launches to enhance the Victoria's Secret brand and accelerate our beauty business, a reimagined merchandise strategy for our PINK brand, and the return of our iconic fashion show with the Victoria's Secret World Tour '23."

16:24 EST Mueller Water delays 10-K due to previously announced cybersecurity incident - In a regulatory filing, Mueller Water Products said that, as previously announced on October 28, Mueller Water Products identified a cybersecurity incident impacting certain internal operational and information technology systems. "Based on the information reviewed to date, the company believes the unauthorized activity has been contained. All of the company's facilities are operational and have substantially returned to normalized operations. This cybersecurity incident consisted of unauthorized access and deployment of ransomware by a third party to a portion of the company's internal information infrastructure. The incident caused disruptions and limitation of access to portions of the company's business applications supporting aspects of the company's operations and corporate functions, which limited the company's ability to take orders and ship products. The company has largely restored the impacted applications and systems, and continues to execute business continuity and restoration plans for the remaining impacted applications and systems. This cybersecurity incident disrupted access to certain systems and information required for the company's financial reporting. After restoring access to such systems and information, the company has focused on verifying its data and completing its fiscal 2023 processes. Due to the timing of the incident, the company will be delayed in filing its Annual Report on Form 10-K for the year ended September 30, 2023. However, the company currently expects to report its fiscal fourth quarter and fiscal 2023 results and file its Form 10-K no later than December 14, 2023, which is within the Rule 12b-25 period available to the company for its Form 10-K. When the company has greater certainty on the timing of the completion of its financial close and reporting processes, the company will make an announcement related to the timing of its fourth quarter and fiscal 2023 earnings release and conference call. The company also identified a separate cybersecurity incident, which primarily related to a system that was end of life and was already in the process of being replaced in the ordinary course of business. The company's investigation and remediation efforts remain ongoing, including the analysis of data accessed, exfiltrated or otherwise impacted in connection with the cybersecurity incidents. The company continues to evaluate the business, financial and related impacts of the cybersecurity incidents," the filing stated.

16:23 EST TechPrecision to purchase Votaw Precision Technologies for $85M - TechPrecision announced that it has entered into a definitive agreement to purchase all of the outstanding shares of Votaw Precision Technologies for $85M on a cash and debt free basis. Located in Santa Fe Springs, California, Votaw is a privately-held operating company of Doerfer Corporation. Upon completion of the acquisition, Votaw will become a wholly owned subsidiary of TechPrecision. TechPrecision will pay $70M to Seller at closing. TechPrecision will be obligated to pay up to an additional $25M as an earnout payment; to be paid out over three years starting June 30, 2024, based on Votaw's FY2024 EBITDA. The earnout payment will be determined by a formula based on Votaw's achieving FY2024 of EBITDA over $11.175M and will be $25M if EBITDA is at least $14.1M. Seller is paying for up to three new machines currently being installed or scheduled to be installed in calendar year 2024, at a cost to it of up to approximately $6.6M. The acquisition is expected to be completed between December 15, 2023, and March 31, 2024, subject to the satisfaction of customary closing conditions. TechPrecision has 45 days from the date of signing to complete its ongoing due diligence to its satisfaction or terminate the SPA without recourse.

16:19 EST Nu Skin opens new manufacturing facility in China - Skin Enterprises announced the opening of its new manufacturing facility in Shanghai, China. Nu Skin has invested approximately $55M in the new facility over the past few years, which will increase production capacity and supply chain responsiveness for the company in China and its other Asian markets. The modern facility in the Fengxian District of Shanghai is 440,000 square feet and was also designed and constructed in accordance with green building standards, maintaining a high production capacity while conserving energy and reducing water consumption. More than 200 guests attended the grand opening, representing local government, industry associations and consumer associations.

16:19 EST Discover to explore sale of Discover Student Loans portfolio - Discover Financial Services announced that the company's board of directors has authorized Discover management to explore the sale of the Discover Student Loans portfolio and the transfer of servicing of these loans to a third-party provider as it pursues strategic alternatives for the Discover Student Loans business. Additionally, Discover will stop accepting new applications for student loans February 1, 2024. There is no impact to current Discover Student Loans customers or their loans or payments at this time. "Discover's Board regularly reviews the strategic fit of all of our businesses, with a focus on providing exceptional customer service and allocating resources to optimize returns. During a recent review, the Board determined that exploring the sale and transfer of servicing of Discover's student loans is aligned with those priorities, better enabling Discover to focus on our core banking products, capitalize on our growth opportunities and deliver long-term shareholder value. We are committed to a path forward that enables a seamless transition for our customers as they advance their education and financial goals," said John Owen, Discover's interim CEO and President. Discover has retained Wells Fargo Securities, LLC as its financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as its legal advisor to support its exploration of strategic alternatives for Discover Student Loans.

16:16 EST Desktop Metal receives continued listing standard notice from NYSE - Desktop Metal announced that it received notice from the New York Stock Exchange on November 22, 2023, indicating that Desktop Metal is not in compliance with NYSE's continued listing standards because the average closing price of Desktop Metal's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of Desktop Metal's common stock from the NYSE. Under NYSE rules, Desktop Metal has a period of six months from receipt of the notice to regain compliance with the NYSE minimum stock price listing requirement. Desktop Metal has notified the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE continued listing standards. Desktop Metal intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to stockholder approval no later than at Desktop Metal's next annual meeting of stockholders, if necessary, to cure the stock price non-compliance. Under the NYSE's rules, if Desktop Metal determines that it will cure the stock price deficiency by taking an action that will require stockholder approval at its next annual meeting of stockholders, the price condition will be deemed cured if the price promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days.

16:13 EST Nutanix jumps 6% to $44.20 after Q1 earnings beat, guidance raise

16:11 EST 3D Systems director Erickson buys 50,000 common shares - In a regulatory filing, 3D Systems director Thomas Erickson disclosed the purchase of 50,000 common shares of the company on November 28 at a price of $5.30 per share.

16:11 EST Nutanix reports Q1 ACV Billings up 24% from last year at $287.2M - Reports Q1 ARR up 30% from last year at $1.66B.

16:07 EST Ralph Lauren CEO Louvet sells $12M in company shares - Ralph Lauren CEO Patrice Louvet disclosed the sale of 95,754 shares of company stock at $124.93 per share on November 27 for a total transaction amount of $11,962,54. *

16:00 EST TechPrecision Corp trading halted, news pending

15:56 EST Altamira Therapeutics spikes 170% after regaining compliance with Nasdaq - Shares of Altamira Therapeutics are up 40c or 170% to 62c per share in late afternoon trading on Wednesday after announcing that it recently received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum stockholders' equity requirement as set forth under Nasdaq Listing Rule 5550b1 for continued listing on Nasdaq. The Company had boosted its equity position through a public offering of common shares in July, the partial amortization of convertible debt granted by FiveT Investment Management as well as, most recently, the partial spin-off of its Bentrio activities. The Bentrio transaction involved the spin-off of a 51% stake in its subsidiary Altamira Medica , as a strategic move to reposition Altamira Therapeutics as an RNA delivery technology company. Bentrio is a drug-free OTC nasal spray utilized for the treatment of allergic rhinitis. The transaction closed on November 21 during which Altamira received a cash consideration of CHF 2,040,000, approximately $2.3M. The Company retains a 49% stake in Medica, which will be consolidated as an 'associated company' and will be entitled to receive 25% of its future licensing income.

15:21 EST Danaher seeing 'anecdotal stories' of customers suddenly requiring volumes - Speaking at the Evercore ISI HealthCONx Conference, executives from Danaher stated in part, according to a transcript: "Certainly, our customers are also keen and bringing their own inventory levels down as the cost of capital has increased. And so we're very, very closely aligned here with our customers. And we have seen consistently, if you will, the book to bill rate here over the various quarters, be consistent. And frankly, we have, you know, also anecdotal stories of, you know, customers suddenly requiring volumes they're, you know, lower on their inventories. And while those are not yet data points that we would use to make any projections in previous quarters, you didn't have these kind of anecdotes where customers would suddenly require a rush order, if you will. So we see that and we continue to watch it. We like more than a couple of data points. We like data series. And as we finish up this quarter and get to our January earnings call, we'll talk about what all that means for 2024."

14:46 EST CF Acquisition Corp VIII trading resumes

14:42 EST Disney's Iger says ABC network TV business not for sale - Disney CEO Bob Iger said while being interviewed at The New York Times' DealBook conference that ABC and the linear network TV business is not for sale, but that the company is "constantly evaluating" assets and how they fit within Disney. Iger also said he "will definitely step down" when his contract is up at the end of 2026.

14:03 EST Vertex says Health Canada grants expanded use of Kalydeco - Vertex Pharmaceuticals announced that Health Canada has granted market authorization for the expanded use of Kalydeco for the treatment of cystic fibrosis in children ages two months and older weighing at least three kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D,G178R, G551S, S1251N, S1255P, S549N, S549R or R117H. "For the first time, children with specific mutations will be eligible at 2 months of age for a medicine that treats the underlying cause of their cystic fibrosis," said Michael Siauw, General Manager at Vertex Pharmaceuticals.

13:42 EST Netflix adds Grand Theft Auto: The Trilogy, to its games menu for holiday - Netflix will debut the Grand Theft Auto: The Trilogy, The Definitive Edition, to its game slate for the holiday season. Earlier on Wednesday the Netflix Staff announced: "Three iconic locations, three epic stories. Rockstar Games' Grand Theft Auto: The Trilogy - The Definitive Edition is coming to Netflix on December 14 for Netflix members on the App Store, Google Play, and in the Netflix mobile app..fans can pre-register to play Grand Theft Auto: The Trilogy - The Definitive Edition, featuring the genre-defining titles of Grand Theft Auto III, Grand Theft Auto: Vice City, and Grand Theft Auto: San Andreas, each updated for mobile. Grand Theft Auto III - The Definitive Edition: Welcome to Liberty City. Where it all began. With a massive and diverse open world, a wild cast of characters from every walk of life, and the freedom to explore at will, Grand Theft Auto III puts the dark, intriguing, and ruthless world of crime at your fingertips. Grand Theft Auto: Vice City - The Definitive Edition: Welcome to the 1980s. From the decade of big hair and pastel suits comes the story of one man's rise to the top of the criminal pile. Grand Theft Auto returns with Tommy Vercetti's tale of betrayal and revenge in a neon-soaked tropical town full of excess and brimming with possibilities. Grand Theft Auto: San Andreas - The Definitive Edition: It's the early '90s. After a couple of cops frame him for homicide, Carl 'CJ' Johnson is forced on a journey that takes him across the entire state of San Andreas, to save his family and to take control of the streets. rand Theft Auto: The Trilogy - The Definitive Edition adds to a growing catalog of more than 80 mobile games, with must-play titles across all genres adding further value to all Netflix memberships - including through one of the most iconic series in history, without any ads, in-app purchases, or extra fees." Reference Link

13:29 EST North American rail traffic up 1.7% for the week ending November 25 - The Association of American Railroads or AAR, reported U.S. rail traffic for the week ending November 25. For this week, total U.S. weekly rail traffic was 415,332 carloads and intermodal units, up 2.4% compared with the same week last year. Total carloads for the week ending November 25 were 195,948 carloads, down 2.% compared with the same week in 2022, while U.S. weekly intermodal volume was 219,384 containers and trailers, up 7.1% compared to 2022. Four of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included petroleum and petroleum products, up 1,034 carloads, to 8,642; metallic ores and metals, up 880 carloads, to 18,457; and chemicals, up 505 carloads, to 27,582. Commodity groups that posted decreases compared with the same week in 2022 included miscellaneous carloads, down 3,804 carloads, to 6,256; nonmetallic minerals, down 1,701 carloads, to 21,525; and grain, down 1,328 carloads, to 17,961. North American rail volume for the week ending November 25 on 12 reporting U.S., Canadian and Mexican railroads totaled 302,649 carloads, down 2.3% compared with the same week last year, and 299,802 intermodal units, up 6.1% compared with last year. Total combined weekly rail traffic in North America was 602,451 carloads and intermodal units, up 1.7%. North American rail volume for the first 47 weeks of 2023 was 30,823,776 carloads and intermodal units, down 3% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) ,Union Pacific (UNP), Greenbrier (GBX),Trinity Industries (TRN), Wabtec (WAB), FreightCar America (RAIL), and Rail Vision (RVSN). Reference Link

12:27 EST Cenntro Electric announces reverse stock split to regain Nasdaq compliance - Cenntro Electric Group Limited announced that it will effect a 1-for-10 reverse stock split of its outstanding common stock to seek to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) by the December 18, 2023 deadline. The company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis when the market opens on Friday, December 1, 2023, and will continue to trade under the symbol "CENN." The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 304,449,091 shares to approximately 30,444,910 shares, plus any shares to be issued in exchange for fractional interests.

12:00 EST NET Power falls -8.8% - NET Power is down -8.8%, or -86c to $8.96.

12:00 EST CoreCard falls -17.2% - CoreCard is down -17.2%, or -$2.68 to $12.94.

12:00 EST GameStop rises 20.2% - GameStop is up 20.2%, or $2.73 to $16.22.

11:58 EST WeTrade discloses that Q3 financial report is 'untrue' - WeTrade disclosed that the third quarter financial statements released by WeTrade Group were not signed and released by the current management of the company. "According to the financial report, as of September 30, 2023, there were no legal proceedings.However, in July 2023, there were still legal lawsuits filed by the company regarding contract disputes, which were also presented in Chinese Qichacha.And meanwhile,The former management, current management, and shareholders have been in multiple lawsuits since September, with the latest hearing date being December 5, 2023." Incorrect information also includes administration address and cash amounts held, WeTrade said.

11:33 EST Lowe's, Charlotte Hornet's extend long-term partnership - Lowe's Companies, Inc. and the Charlotte Hornets announced an extension of their long-term partnership in which the Mooresville-based company remains a Founding Level Partner and the team's Official Home Improvement Retailer. Under the multi-year agreement, Lowe's and the Hornets will continue to prioritize community engagement, which has been a key component of the partnership, including the annual Hornets Legacy Project Powered by Lowe's that aims to improve neighborhoods across Charlotte. Additionally, Lowe's welcomes Hornets legend and North Carolina Sports Hall of Famer Tyrone Curtis "Muggsy" Bogues to the Lowe's Home Team, a move that expands the Lowe's Home Team's roster of athletes to include professional basketball. The Lowe's Home Team is comprised of talented present and past athletes who team up with Lowe's red vest associates and inspire people to tackle home projects with top product picks and helpful expertise, and to better their communities through leading by example.

11:05 EST Sunrise New Energy unit Sunrise Guizhou secures $28M investment - Sunrise New Energy Co., Ltd. announced its subsidiary, Sunrise Guizhou New Energy Materials Co., Ltd. has secured a $28M investment. Sunrise Guizhou has already signed an investment agreement with the investor, stating the investment funds will be realized within 60 working days. "We are delighted that this investment will effectively supplement the company's cash flow, which will greatly assist in fulfilling the delivery of our existing substantial orders." stated Sunrise's Chairman, Haiping Hu. "We have successfully secured orders from esteemed clients, including the world's largest power battery manufacturers, CATL and BYD, as well as several top-ranking energy storage battery companies. Our commitment to excellence in product quality, technological innovation, and customer satisfaction has enabled us to forge strong partnerships with industry leaders."

10:40 EST Elliott seeks Phillips 66 board seats, sees 75% share upside - Elliott Investment Management confirmed this morning that it manages funds that together have an approximately $1B investment in Phillips 66 (PSX) and that it sent a letter today to the board of Phillips 66. In its letter, Elliott "outlined a path by which Phillips 66 can remedy its underperformance, improve its execution, restore trust with investors and unlock significant and sustainable value for its shareholders. Elliott sees approximately 75% upside to the current stock price." Elliott said that while the company's 2025 targets "are admirable, investors are skeptical of the Company's ability to achieve them." Elliott wrote, "At present we believe Mr. Lashier and the rest of the management team deserve investor support so long as they demonstrate meaningful progress against these targets. At the same time, we find the market's skepticism to be understandable, and we believe the Board must take several steps to reassure investors that Phillips 66 is in the best possible position to achieve its value-creation potential." Among the steps Elliott recommended is the appointment to the Phillips 66 board of two new directors. "Should Phillips 66 be unable to deliver on its 2025 targets, Elliott believes the Company could successfully implement a similar path to the one Marathon Petroleum Corporation (MPC) followed after its engagement with Elliott in 2019," the activist said.

10:30 EST Proof Acquisition I Corp trading halted, volatility trading pause

10:18 EST Tyson Foods opens new $300M fully-cooked food production plant in Virginia - Tyson Foods has officially opened a new $300M fully-cooked food production facility in Danville, Virginia, delivering on its strategy of accelerating long-term growth, operating as efficiently as possible and investing in its poultry business. It is one of the company's most-automated plants to date, marking the deployment of innovation pilots and prototypes at scale. The 325,000-square-foot facility represents a significant investment in the local community and will produce approximately four million pounds of premium quality, fully-cooked poultry products weekly to meet the increasing demand for iconic Tyson brand products, both in retail and foodservice. Located in the Cane Creek Centre, a local business park owned by the City of Danville and Pittsylvania County, the facility has created nearly 400 new jobs for the southeastern Virginia region.

10:08 EST Union Pacific announces new international intermodal terminal in Phoenix - Union Pacific Railroad announced plans today to open a new international intermodal terminal in the heart of Phoenix, providing customers a sustainable rail option between ocean ports in the Los Angeles Basin and the nation's fast-growing Southwest region. The new terminal, owned and operated by Union Pacific, is expected to open in the first quarter of 2024. It will be established in Union Pacific's downtown rail yard, with capacity to grow to meet customer demand. The new facility will open with drayage support provided by Duncan & Son Lines, a family-owned logistics firm in Buckeye, Arizona, that primarily focuses on international container drayage from the ports of Long Beach and Los Angeles. The new terminal further expands Union Pacific's intermodal footprint, which is the largest in North America with the most direct services from coast to coast.

10:00 EST Direxion Daily Semiconductor Bear 3X Shares falls -7.2% - Direxion Daily Semiconductor Bear 3X Shares is down -7.2%, or -62c to $7.94.

10:00 EST CoreCard falls -17.4% - CoreCard is down -17.4%, or -$2.72 to $12.90.

10:00 EST Foot Locker rises 20.4% - Foot Locker is up 20.4%, or $4.86 to $28.70.

09:58 EST Edgewise Duchenne and Becker Muscular Dystrophy treatment granted orphan status - Edgewise Therapeutics' Duchenne and Becker Muscular Dystrophy treatment was granted FDA orphan status, according to a post to the agency's website. Reference Link

09:47 EST CoreCard falls -8.6% - CoreCard is down -8.6%, or -$1.34 to $14.28.

09:47 EST General Motors rises 11.3% - General Motors is up 11.3%, or $3.27 to $32.16.

09:47 EST GameStop rises 19.6% - GameStop is up 19.6%, or $2.65 to $16.14.

09:43 EST Knightscope begins selling automated gunshot detection systems - Knightscope announced the commencement of sales for its Automated Gunshot Detection systems for both indoor and outdoor environments. AGD is now available as stand-alone sensors mounted to existing structures or with the optional pole-mounting kit and solar power for installation flexibility. In the coming weeks, Knightscope clients will have the option to add AGD onto new K1 Blue Light Tower orders or to upgrade the over 7,000 devices already deployed across the country.

09:40 EST Eagle Pharmaceuticals trading resumes

09:36 EST WidePoint's IT Authorities awarded $900,000 contract for Cisco equipment - WidePoint Corporation (WYY) announced that its subsidiary IT Authorities has been awarded a new contract valued at $900,000 for Cisco (CSCO) equipment by a national bottling distributor.

09:35 EST TSR trading resumes

09:34 EST Holland America reports Black Friday booking volume up over 20% vs. last year - For the second year in a row, Holland America Line's Black Friday booking volumes broke a record high for the shopping holiday in the United States, with volume for the day more than 20% higher than last year's record high and 23% higher for the period from Black Friday through Cyber Monday. The trend was especially noticeable with guests planning summer vacations in 2024, with bookings for Alaska, Europe and Canada/New England all surpassing volumes from last year's Black Friday sales. "While some see Black Friday as a sign that winter is coming, our guests were dreaming about exploring summer destinations like Alaska, Iceland and Greece," said Gus Antorcha, president, Holland America Line. "Breaking Black Friday records two years in a row tells us that not only are guests excited to plan ahead for travel, but that they value Holland America Line's award-winning service and carefully crafted itineraries that visit more than 100 countries."

09:30 EST TSR trading halted, volatility trading pause

09:24 EST WISeKey, SEALSQ partner with DP World for smart container integration - WISeKey International and DP World announced a landmark Memorandum of Understanding signed on 19 November. This MOU marks the beginning of a collaborative venture aimed at transforming the logistics industry through innovative technology by integrating in a single window enterprise multi-vendor platform for sea, air and land. The MOU sets the stage for integrating IoT-enabled devices and IoT sensors into smart containers to be tracked and trace by the WISeSat constellation and earth communication infrastructures. This initiative will create a seamless, secure platform with hybrid IoT communications. The implementation of this technology promises to revolutionize global track and trace capabilities for shipping containers, enhancing transparency, security, and operational efficiency. Key aspects of the MoU: Integration of IoT Technologies: The plan involves incorporating IoT-enabled devices and sensors in smart containers. These containers will be monitored and traced by the WISeSat satellite constellation, creating a secure, hybrid IoT communication platform. This technology aims to enhance global tracking and transparency for shipping containers, boosting security and operational efficiency. Advanced Container Monitoring: Containers will be fitted with IoT devices secured by WISeSAT IoT sensors, allowing real-time tracking of their location and condition. This integration of satellite and terrestrial IoT communications ensures constant global connectivity. Sustainable and Efficient Logistics: Aligning with DP World's sustainability goals, this initiative intends to optimize routes and reduce carbon emissions. It promises to set new efficiency standards in logistics, minimizing delays, errors, and costs. Collaborative Industry Effort: This project is a joint venture between industry leaders, aiming to establish a universally adaptable platform that redefines industry standards. It brings together experts from logistics, cybersecurity, and IoT sectors. Consortium Partners: The project, named the Smart Container Consortium, includes partners like Bernardino Abad S.L., FOSSA Systems, Avant iot, Integral Group, SEALSQ, WISeSAT.Space, and Caspian Container Company. They aim to deploy IoT-enabled devices and sensors in containers for real-time, global tracking via the WISeSat Satellite constellation Technology Integration: The agreement focuses on equipping containers with advanced WISeSAT IoT sensors, secured by SEALSQ semiconductors, providing real-time data on their location, condition, and other vital parameters. The integration of WISeSAT Smart container platform and technology into the CargoES platform ensures trusted and global, real-time tracking and tracing capabilities via the WISeSat Satellite constellation and terrestrial infrastructures enabling uninterrupted connectivity worldwide. co-Conscious and Efficient Logistics: The integration of these smart containers aligns with WISeKey and DP World's commitment to sustainability, aiming to optimize routes and reduce carbon emissions. This eco-friendly approach also sets new benchmarks in logistical efficiency, reducing delays, errors, and overall operational costs. Collaborative Effort and Industry Standards: This venture is a collaborative effort involving industry pioneers, aiming to create a universally adaptable platform that redefines industry standards. The initiative brings together experts from various sectors, including logistics, cybersecurity, and IoT, to architect and advocate this unified system. As a first client of this initiative up to 20,000 containers from Caspian Container company will be equipped and connected during 2024. The Parties will undergo a thorough due diligence process, aiming to finalize the definitive agreements within 45 days from the receipt of proposals. The MOU outlines specific conditions precedent and the process for reaching an agreement on the project's structure and management.

09:13 EST Banxa Holdings announces audit update - Banxa Holdings announces an update on the FY23 audit. Banxa's audit partner, PKF Antares has continued to make good progress in the final review stage with its Senior Partners. The revised anticipated timeline for the FY23 audit completion is December 8, 2023. The timeline has been revised due to the additional substantiation needed by PKF on Banxa's agency revenue recognition policy. Banxa has engaged a reputable third party accounting firm to provide an independent opinion on the agency revenue recognition policy. The independent opinion on Banxa's agency revenue recognition policy is expected to be finalized this week. If this independent review does not support Banxa's agency revenue recognition policy or PKF is not satisfied with the independent review, then the audit sign-off may be delayed further. However, Banxa's Board and Management anticipate the independent review to be in support of Banxa's agency revenue recognition policy - which has been reviewed and signed off across multiple prior audits - and at this time do not anticipate further delays to arise in the audit's completion. The agency revenue recognition policy has no impact on Banxa's gross profit, net income, or cash position. Banxa has a healthy sales pipeline and is in a stronger financial position after raising CAD$5.5M.

09:09 EST Appen appoints Alicia Hale as CMO - Appen Limited announced the appointment of Alicia Hale as Chief Marketing Officer. In her most recent role, Hale served as CMO of Tempo Software, overseeing the company's brand management, product repositioning, and analyst relations efforts.

09:08 EST Rover Group to be acquired by Blackstone for $11.00 per share in cash - Rover Group (ROVR) has entered into a definitive agreement to be acquired by private equity funds managed by Blackstone (BX) in an all-cash transaction valued at approximately $2.3 billion. Under the terms of the agreement, Rover stockholders will receive $11.00 per share in cash, representing a premium of approximately 61% to the volume weighted average share price of Rover's Class A common stock over the 90 trading days ending on November 28, 2023. Rover was created to provide an alternative to relying on friends, family, neighbors, and/or boarding facilities for pet care when traveling away from home. Over the years, offerings on Rover have grown to include five core services addressing daytime and overnight needs. From its inception through September 30, 2023, over 93 million services have been booked by more than 4 million pet parents on Rover with more than 1 million pet care providers paid across North America and Europe. Through its platform and mobile app, pet parents can easily discover, book, re-book, pay, and review loving pet care providers online. Rover eliminates many of the barriers of pet ownership, enabling the Company's mission to make it possible for everyone to experience the unconditional love of pets. Rover's partnership with Blackstone reflects a shared belief in the future growth potential of the industry and long-term vision to build on Rover's leadership position in the market. Blackstone's investment aims to help enable Rover to further accelerate investment priorities, expand its global footprint, and fuel expansion initiatives. The merger agreement includes a customary 30-day "go-shop" period expiring on December 29, 2023. During this period, Rover and its advisors will be permitted to solicit, consider and negotiate alternative acquisition proposals from third parties. The Rover board of directors will have the right to terminate the merger agreement to enter into a superior proposal, subject to the terms and conditions of the merger agreement. There can be no assurance that this "go-shop" process will or will not result in a superior proposal, and Rover does not intend to disclose related developments unless and until it determines that such disclosure is appropriate or otherwise required. The transaction is currently expected to close in the first quarter of 2024, subject to the approval of Rover's stockholders and the satisfaction of required regulatory clearances and other customary closing conditions. The Rover board of directors approved the merger agreement and recommended that Rover stockholders approve the transaction and adopt the merger agreement. Closing of the transaction is not subject to a financing condition. Upon completion of the transaction, Rover's Class A common stock will no longer be publicly-listed and Rover will become a privately held company. The Company will continue to operate under the Rover name and brand.

09:06 EST Gulf Island Fabrication receives multiple subsea fabrication awards - Gulf Island Fabrication announced that it has been awarded multiple subsea fabrication projects from a leading integrated subsea engineering, procurement, construction and installation, EPCI, company. The projects consist of procurement, fabrication, coating and testing of subsea structures for multiple developments located in the Gulf of Mexico. The fabricated components include PLETs, jumper kits, jumpers and sleepers that will be fabricated at Gulf Island's Houma fabrication facility. The aggregate contract value for the various awards is approximately $5 million and they will be included in the Company's new awards and backlog in the fourth quarter 2023. "Several years ago, we made a strategic decision to focus resources on the subsea fabrication market, so we are excited to see momentum building in this market, with these recent awards validating our strategy," said Richard Heo, Gulf Island's President and Chief Executive Officer. "We expect subsea fabrication activity to remain strong well into 2024, associated with anticipated subsea developments across the Gulf of Mexico, Guyana and Brazil, and Gulf Island is well-positioned to take advantage of these trends. We are proud to have been chosen for these critical projects and look forward to expanding our relationship with this customer."

09:05 EST CareCloud Concierge chosen by Broadway Foot & Ankle Clinic - CareCloud announced Broadway Foot & Ankle Clinic, a podiatry practice in Portland, Oregon, has chosen to implement CareCloud Concierge, a tech-enabled revenue cycle management solution. Already using CareCloud's electronic health records and practice management system, Broadway Foot & Ankle Clinic decided to expand its collaboration with CareCloud due to their familiarity with the platform and its outstanding track record in the healthcare industry. "CareCloud Concierge is a seamless addition to Broadway Foot & Ankle Clinic," said Ashley Bello, director of client sales at CareCloud. "Given their familiarity with the CareCloud platform, this integration complements their existing solutions perfectly. CareCloud Concierge is the solution to addressing the multitude of challenges Broadway Foot & Ankle Clinic faces in revenue cycle management, from intricate coding to high denial rates, and the time-consuming billing process. By leveraging CareCloud Concierge, Broadway Foot & Ankle Clinic can enhance their RCM efficiency, reduce accounts receivable, and ultimately contribute to boosting profitability."

09:05 EST MultiMetaVerse announces termination of acquisition agreement of Taomee - MultiMetaVerse Holdings announced that it has received a letter of termination with respect to MMV's contemplated acquisition of Taomee. On September 15 MMV announced that it had entered into an acquisition agreement to acquire 100% equity in Shanghai Shengran Information Technology and associated interests pertaining to all of its consolidated variable interest entities. The closing of the Agreement was conditioned upon, among others, MMV's payment of the transaction consideration in installments within a fixed period of time. MMV received the Letter of Termination from Dongzheng Ruibo Investment Center and Orient TM Ruibo terminating the Agreement citing MMV's inability to pay the consideration within the agreed timeline pursuant to the Agreement. MMV believes that the Target Group is a valuable asset with synergy to the Company, and intends to further pursue the transaction contemplated under the Agreement. MMV continues to engage the Sellers in negotiation regarding the acquisition of Taomee and is optimistic of the possibility of resuming the transaction when MMV secures sufficient funding for closing. In furtherance of this effort, MMV is actively seeking financing opportunities with institutions and private investors. In particular, MMV has entered into a share subscription agreement with Eagle Creek with a total proceed of $15M. MMV's management is committed to raising additional funds in an effort to close the transaction.

09:04 EST STMicroelectronics collaborates with indie Semiconductor - STMicroelectronics (STM) has introduced the STSAFE-V100-Qi secure element to strengthen privacy and security when charging car occupants' portable devices. ST also revealed its collaboration with indie Semiconductor (INDI), a pure-play automotive semiconductor company, to integrate the new secure element in indie's Qi wireless in-car charging reference design. ST's new IC enables in-car charging to meet the latest Wireless Power Consortium specifications, which call for protection by a secure element. It is also certified to the highest level of security applicable for Qi chargers, common criteria EAL4+, ensuring heightened cybersecurity protection. "By integrating our STSAFE-V100-Qi, the reference design meets the latest WPC specification and Common Criteria EAL4+ to assure protection of charging devices at up to 15W," said Laurent Degauque, Marketing Director, Connected Security, STMicroelectronics. "As a result, indie's customers benefit from a powerful combination of a high-quality charging system with the highest level of security."

09:04 EST AvidXchange enters partnership with M3 Accounting Solutions - AvidXchange announced a partnership to provide hotels a fully automated financial management solution. As part of this partnership, M3 will embed AvidXchange's industry-leading payment automation technology into CoreSelect, its latest cutting-edge accounting offering, providing the industry a more efficient and accurate way to manage its deeply complex payments process. The CoreSelect offering is tailored to seamlessly integrate with day-to-day hotel financial operations and reporting, delivering efficiency to M3 customers. This integration provides customers with additional efficiencies as AvidXchange offers complete vendor and payment management, which can result in significant time and cost savings by reducing the need to support this need manually through a paper-based process.

09:02 EST Elevai Labs enters licensing agreement with Yuva Biosciences - Elevai Labs announced that they have signed a licensing agreement with Yuva Biosciences to research and develop means to incorporate Yuva Bioscience's mitochondrial research with ELEVAI's PREx to potentially develop topical skincare formulations that combine mitochondrial biology with Elevai's human umbilical mesenchymal stem cell derived exosomes. Elevai currently markets its proprietary ELEVAI E-Series which are peri-procedure topical exosome skincare products. Yuva Biosciences utilizes mitochondrial science to address signs of aging of hair, scalp, and skin. "We are excited to partner with Yuva Biosciences in order to begin research and development of products that may incorporate the power of mitochondrial technology to further advance the potential of Elevai exosomes to address cosmetic skin and hair concerns associated with signs of aging," said Jordan R. Plews PhD and CEO of ELEVAI Labs.

09:01 EST LPL Financial appoints McHale as EVP, CCO - LPL Financial (LPLA) announced Executive Vice President, EVP, and Chief Compliance Officer, CCO, Jim McHale has joined the firm. McHale will lead LPL's compliance organization, helping to drive a strong risk management culture in an ever-evolving regulatory environment. He reports to Executive Vice President and Chief Risk Officer Brent Simonich. McHale joins LPL from Wells Fargo (WFC), where he most recently served as executive vice president and head of compliance for the Wealth and Investment Management Division.

08:59 EST Metals Company announces Benchmark study on impacts of nickel, cobalt mining - TMC the metals company announced that Benchmark Mineral Intelligence has completed an independent third-party study of how terrestrial cobalt mining in the woodland forests of the Democratic Republic of Congo and nickel mining in the rainforests of Indonesia impact terrestrial carbon sinks. The full study can be downloaded here and a summary document here. While awareness is growing of the direct carbon emissions from metals mining and processing, lifecycle assessments do not often assess the impacts of land-use change on carbon sinks in specific regions. The new Benchmark study complements their earlier independent third-party lifecycle assessment where the environmental impacts of TMC's planned NORI-D Polymetallic Nodule Project are compared to the lifecycle impacts of key-land based production routes for nickel, cobalt and copper. Benchmark focused on DRC and Indonesia and set out to quantify the loss of carbon stocks and sequestration services caused by the mining of cobalt in the region of Katanga, DRC and nickel in Sulawesi, Indonesia. Benchmark data was used to select five of the largest mines in each region as case studies, which then underwent Geographical Information System mapping analysis to look at changes over a 14-year period. Habitat types were defined using the Land Cover Classification System to assess the changes and impact that mining had on regional carbon stocks during that same period. In both Indonesia and the DRC, the extraction of metal ores through open pit mines requires the complete removal of overlying ecosystems and contained carbon sinks, in turn eliminating the carbon sequestration services they provide. The study found that 1 kg of nickel mined from saprolite and limonite ore in Sulawesi removes forests containing carbon stock equivalent to 7.0 and 9.4 kg of CO2e, and 3.6 kg of CO2e in the case of cobalt mined in Katanga. Due to the resulting vegetation change, mining activities cause carbon sequestration services loss of 4.8 g and 6.5 g of CO2e respectively for nickel, and 9.3g of CO2e for cobalt per year. Furthermore, Benchmark reported an average area of vegetation change of 2.6 million square meters and 1.4 million square meters per year respectively for each nickel and cobalt case study mine over the period assessed by GIS. This activity results in the loss of 443,000 tonnes CO2e and 57,000 tonnes CO2e of carbon sinks per year and the annual loss of 309 tonnes CO2e and 147 tonnes CO2e of carbon sequestration services, for nickel and cobalt respectively. When combining the findings of this latest study on carbon stock loss with the GHG emissions quantified in Benchmark's earlier study, the total carbon impacts of Indonesian nickel production from laterites via RKEF and HPAL routes increase by between 7-49% respectively, and by 35% in the case of cobalt production from mixed sulfides in the DRC. In January 2022, TMC announced the publication of a peer-reviewed study in the Yale Journal of Industrial Ecology which found that seafloor polymetallic nodules could significantly reduce-and in some scenarios eliminate-the onshore solid waste streams typically generated by metal production from land ores. An earlier peer-reviewed study - published in the Journal of Cleaner Production - found that sourcing critical battery metals from seafloor nodules could drastically reduce the lifecycle climate change impacts when compared to land ores.

08:52 EST Global-e Online appoints Gen Tsuchikawa to board of directors - Global-e Online announced that Mr. Gen Tsuchikawa, CEO of Sony Ventures Corporation, has joined the board of directors as an independent member, effective as of November 29, 2023. Tsuchikawa will serve as a non-executive director and as a member of the board of directors' Compensation Committee and Nominating, Governance and Sustainability Committee, in replacement for Mr. Thomas Studd, a partner at Vitruvian Partners, who has recently stepped down from the board.

08:47 EST AbbVie announces results from single-arm Phase 2 LUMINOSITY trial - AbbVie announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin in patients with c-Met protein overexpression, epidermal growth factor receptor wild type, advanced/metastatic nonsquamous non-small cell lung cancer, or NSCLC. The results demonstrated a compelling overall response rate per independent central review, or ICR, of 35% and 23% across c-Met High and c-Met Intermediate patients respectively. In addition, other endpoints demonstrated meaningful clinical outcomes including median duration of response per ICR of 9 months and 7.2 months and a median overall survival of 14.6 months and 14.2 months across c-Met High and c-Met Intermediate patients respectively. The safety profile of Teliso-V was consistent with previous findings and no new safety concerns were identified. Approximately 85% of lung cancers are classified as NSCLCand despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths in both men and women throughout the world. C-Met protein overexpression is found in approximately 25% of advanced EGFR wild type NSCLC patients3 and is associated with a poor prognosis for these patients.4,5,6 Teliso-V, an investigational ADC, is being studied in this patient population who have very limited treatment options and where there are currently no approved therapies.

08:40 EST GM says must be 'conscious' of potentially higher supplier labor costs in 2024

08:38 EST NewtekOne launches Newtek Accounting - NewtekOne has partnered with 1-800Accountant for NewtekOne to offer 1-800Accountant's accounting services to NewtekOne's independent business owner clients and referral partners via "Newtek Accounting". Through Newtek Accounting, NewtekOne's clients will have access to 1-800Accountant's suite of professional accounting services, which is powered by both a mix of technology and CPAs with an average of 17 years of experience. This product offering will enable NewtekOne to augment its already broad suite of business and finance solutions and offer its clients digital bookkeeping, personalized accounting solutions, and tax advisory services underscored by access to experts to assist them with their business' accounting and tax needs, while simultaneously allowing them more time to focus on growing their business.

08:37 EST Dyadic International announces results from Phase 1 trial of DYAI-100 - Dyadic International announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100. This marks the first-in-human use of a recombinant protein vaccine expressed by Dyadic's C1- cell expression platform. The Phase 1 clinical trial was a double-blind placebo-controlled safety study of 30 healthy adults conducted in collaboration with Dyadic's South Africa licensee Rubic One Health. In late 2022, Dyadic received regulatory approval of its Clinical Trial Application, CTA, from the South African Health Products Regulatory Authority, SAPHRA, to conduct the Phase I clinical trial for an antigen produced using its C1-cell protein expression platform. The primary endpoint of the study was to demonstrate the safety and reactogenicity of recombinant proteins. The C1 SARS-CoV-2 RBD single booster vaccine was administered at two dose levels. Top-line safety data confirmed that the study met its primary endpoint demonstrating that both dose levels are safe and well tolerated and that the vaccine produced immune responses at both dose levels. "We are excited to share the top-line results from what we believe marks the first-in-human clinical trial for a vaccine antigen produced using a filamentous fungal cell line, such as our C1 platform," said Mark Emalfarb, CEO of Dyadic. "While vaccines and antibodies produced from our C1-cell protein production platform have previously demonstrated safety and efficacy in animal studies, this trial represents the initial evaluation of a C1-cell produced protein in humans and is clearly a key milestone for the Company. Notably, no Serious Adverse Events were reported, and the clinical study successfully met its primary endpoint demonstrating that a C1 produced antigen was both safe and well-tolerated in both the low and high dose groups."

08:36 EST PBGC renews risk management services contractw ith Ciso Global - The Pension Benefit Guaranty Corporation, PBGC, has renewed its PBGC Office of Benefits Administration Information Systems Security Risk Management Services contract with leading managed cybersecurity and compliance provider CISO Global's wholly owned subsidiary TalaTek. CISO Global's subsidiary TalaTek will continue to support the management and oversight of OBA's compliance and security requirements and its continuous monitoring program that is used to safeguard and protect PBGC's critical systems and data. "As a long-time PBGC partner, we look forward to continuing to help the agency protect its mission-critical operations and strengthen its data security," said Baan Alsinawi, managing director of Strategy & Risk, CISO Global, and founder of TalaTek. "In today's cyber risk environment, it is imperative that federal agencies continuously assess their enterprise environments based on a holistic approach to risk management. We will continue to deliver best-in-class solutions enabled by our team of experts."

08:35 EST Penn Entertainment, NHL enter online sports betting partnership - Penn Entertainment and the National Hockey League, or NHL, announced a partnership that designates Penn's online sports betting brands, ESPN BET in the U.S. and theScore Bet in Ontario, as Official Sports Betting Partners of the NHL. As official league partners, ESPN BET and theScore Bet will have access to a host of entitlements, including IP rights, and media and marketing integrations across League programming and premium NHL experiences. ESPN BET, which launched on November 14 in 17 states, is a newly-branded online sportsbook operated by PENN Entertainment that combines ESPN's industry-leading brand and multiplatform reach with Penn Entertainment's proprietary in-house technology and deep sportsbook operational expertise. Penn's entitlements will begin immediately and span the NHL regular season, Stanley Cup Playoffs, 2024 NHL Winter Classic, 2024 NHL Stadium Series and 2024 NHL All-Star Weekend. The partnership between Penn and the NHL will also include collaboration for best-in-class game integrity procedures.

08:34 EST Actelis Networks receives order from major German energy provider - Actelis Networks announced that it has received a new order to supply a major German provider with its new Encrypted, cyber-hardened, hybrid-fiber networking technology. Actelis continues to expand its solution within the energy sector where data security is critical. "We are seeing more interest from our customers in protecting the edge of their networks with protocols like MACsec encryption," said Tuvia Barlev, Chairman and CEO of Actelis. "Our ability to provide this high level of security over hybrid networks of fiber and legacy wiring, while at the same time also boosting the performance of the existing legacy network with fiber-grade connectivity to be deployed in just hours - is our unique value in the market."

08:33 EST Entera Bio announces interim data from Phase 1 study of oral peptide platform - Entera Bio reported interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic and early pharmacodynamics profile of current and several next generation compositions of its oral peptide platform. EB613 Continues to Display an Optimal Profile as First-in-Class Oral PTH Peptide for Osteoporosis: The Phase 1 study first compared the PK profile of Entera's Phase 3 candidate, oral once-daily PTH mini-tablets with subcutaneous PTH 20 g. Consistent with previously reported PK and bioavailability data, EBP05 induced a rapid and dose-proportional increase in plasma drug concentrations of PTH at all doses tested. The target bioavailability of PTH with EB613 at doses of 1.5 mg and 2.5 mg, covering the dose range planned for phase 3 was met. Additionally, EB613 exhibited consistent and statistically significant effects across all early PD markers such as plasma levels of endogenous PTH, serum calcium, phosphorus, and 1,25-dihydroxyvitamin D. Next Generation Platform Demonstrates Robust Bioavailability with Novel Oral Peptide Compositions: The Phase 1 PK study also assessed novel compositions comprising PTH as a model peptide to test Entera's proprietary, next generation platform. The new compositions show enhanced bioavailability versus our first-generation platform, as expected from pre-clinical data. All formulations demonstrated a consistent PK profile to EBP05 with rapid absorption and elimination; and induced fast PD responses increasing calcium, vitamin D levels along with reducing phosphate and endogenous PTH.

08:32 EST Bristow Group secures early delivery positions for five eSTOL aircraft - Following the successful first flights of Electra.aero, Inc.'s eSTOL technology demonstrator aircraft, Bristow Group secured early delivery positions for five of Electra's hybrid-electric short takeoff and landing, or eSTOL, production aircraft by executing a deposit agreement. Bristow signed a Memorandum of Understanding, or MOU, with Electra in 2021 to be the principal launch operational customer for the eSTOL aircraft, with a pre-order of up to 50 aircraft. Bristow will use Electra's aircraft to expand and diversify its portfolio of specialized passenger services to offer sustainable regional air transport on routes of 50 to 500 miles. The piloted Electra eSTOL aircraft has the unique capability to take off and land in locations as small as 300x100ft, making it ideal for reaching a broader range of remote or underutilized airports as well as alternative landing areas.

08:31 EST GM aiming for single-digit pretax margins on EVs by 2025, says CFO

08:27 EST Satellogic, Tata Advanced Systems in pact to build LEO satelites in India - Tata Advanced Systems Limited or TASL, India's leading private sector player for aerospace and defense solutions, and Satellogic Inc a leader in sub-meter resolution Earth Observation data collection announced their collaboration for establishing and developing local space technology capabilities in India. This collaboration is a first step in TASL's satellite strategy and a significant milestone for Satellogic as it enters the fast-growing Indian defense and commercial market. The project will commence with comprehensive training, knowledge transfer, and local assembly of optical sub-meter resolution EO satellites, the first of which is planned to be launched as TSAT-1A. The focus will be on manufacturing..

08:24 EST General Motors CFO: Labor strike cost 95,000 units of production

08:22 EST General Motors CFO: Underlying business continues to perform well into Q4

08:21 EST Nascent Biotech granted Japanese patent for crossing blood-brain barrier - Nascent Biotech announced the Company has been issued a "Method-of-Use" patent from the Japanese Patent Office for its primary asset, Pritumumab. Specifically, the patent approval is related to PTB's capacity to cross through the Blood-Brain Barrier. The patent allowance recognizes PTB's ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB. In basic terms, the blood-brain barrier is a semipermeable border of endothelial cells that act as a filtering mechanism for the capillaries that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances from the circulatory system into the brain.

08:20 EST Processa Pharmaceuticals issues letter to shareholders - Processa Pharmaceuticals announces that CEO George Ng has issued a letter to shareholders. "Earlier in 2023, the strategic decision was made to focus on development of the Company's Next Generation Chemotherapy agents. That will not change under my direction, and much of my experience is in oncology and leading business transactions. Even with the advent of immuno-oncology and other oncology drugs and treatments, chemotherapy drugs still remain an important and viable treatment option. However, many issues and limitations are associated with the use of chemotherapy.... I think Processa can address these shortcomings with chemotherapy by providing patients with potentially safer and more effective chemotherapy treatments through the pursuit of our Next Generation Chemotherapies... Our current pipeline consists of three separate NGCs in development: NGC-Capecitabine - targeted at colorectal, pancreatic, and other solid tumor cancers; NGC-Gemcitabine - targeted at pancreatic, gall bladder, and non-small cell tumor cancers; NGC-Irinotecan - targeted at pancreatic, ovarian, lung, colorectal, and other cancers. It is important to recognize that each of the respective underlying chemotherapy agents in each NGC candidate are already approved, are on the market, and are used across multiple cancer indications, with each generating between $500 million - $1 billion in worldwide revenue... The current status and upcoming near-term potential milestones for each of our NGCs is follows: NGC-Capecitabine: Phase 1b study enrollment is expected to be completed by early 2024; Assessment of the safety profile of NGC-Cap in totality across all cohorts is expected to be completed by mid 2024; Discussion with FDA to determine Phase 2 study design expected by year-end 2023; With FDA feedback, dose regimen to be used in Phase 2 study is expected to be finalized by mid-2024; Filing of Phase 2 study to the IND is expected by mid-2024; Start of patient enrollment in Phase 2 study is expected in mid-2024. NGC-Gemcitabine: Analysis of existing Phase 2 data from patients with pancreatic cancer under the Project Optimus framework is expected to be completed in early 2024; Discussion with the FDA to determine Phase 2b/3a study design expected in the first half of 2024. NGC-Irinotecan: Analysis of existing pre-clinical data in animals to develop a drug development roadmap is expected to be completed in early 2024; Initiate sourcing of drug substance and product manufacturing sites expected in 2024; Stable Financial Affairs and Business Development Opportunities. ... In conclusion, given our Forward Looking Vision, Experienced Team, De-Risked and Diversified Pipeline, Stable Financial Affairs and Business Development Opportunities, I feel that Processa is well-positioned for success and is uniquely positioned to disrupt and expand current chemotherapy and oncology therapeutics."

08:19 EST GM: New labor deals to add $3/kilowatt-hour to battery cell costs

08:17 EST ENGlobal to effect 1-for-8 reverse stock split - ENGlobal will effect a one-for-eight reverse split of its common stock, effective at 11:59 pm, Eastern Standard Time, on November 30, 2023. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the minimum bid price requirement for continued listing on The Nasdaq Capital Market. As a result of the reverse stock split, every eight shares of the Company's common stock issued and outstanding at the Effective Time will be consolidated into one issued and outstanding share of common stock, with no change in the par value per share of $0.001. Any fractional shares that would otherwise be issued as a result of the reverse stock split will be rounded up to the nearest whole share. The Company's number of authorized shares of common stock will remain at 75,000,000 shares. Trading of the Company's common stock on The Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Friday, December 1, 2023, under the symbol "ENG" and the new CUSIP number 293306205. Immediately after the reverse stock split, the Company expects that there will be approximately 5,125,000 shares of the Company's common stock issued and outstanding. At the Company's annual meeting of shareholders held on June 29, 2023, the Company's shareholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's common stock through an amendment to its Restated Articles of Incorporation, as amended, at a ratio of not less than one-for-two and not more than one-for-ten, with such ratio to be determined by the Company's Board of Directors. The Company has retained its transfer agent, Computershare Trust Company, to act as its exchange agent for the reverse stock split. Computershare will provide shareholders of record as of the Effective Date with instructions for the exchange of their stock certificates. Shareholders holding their shares in book-entry form and/or owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to their brokers' particular processes, and will not be required to take any action in connection with the reverse stock split. The Company also announced that it received a notification letter dated November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market Inc. notifying the Company that it is not currently in compliance with Nasdaq Listing Rule 5550(b)(1) for continued listing due to its failure to maintain a minimum of $2.5 million in stockholders' equity. In the Company's Form 10-Q for the period ended September 30, 2023, the Company reported stockholders' equity of approximately $2.1 million. Nasdaq also determined that the Company does not meet the alternatives of market value of listed securities or net income from continuing operations for continued listing. The notice has no immediate effect on the listing of the Company's common stock. The Company may regain compliance with the minimum stockholders' equity requirement by submitting a plan to regain compliance to Nasdaq by January 8, 2024. If the Compliance Plan is accepted by Nasdaq, the Company may be granted a compliance period of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance. If the Compliance Plan is not accepted by Nasdaq, the Company will have an opportunity to appeal that decision to a Nasdaq Hearings Panel. During the pendency of the hearing process, the Company's common stock would continue to be listed on Nasdaq. the Company's management is considering various options to regain compliance with the minimum stockholders' equity requirement and maintain the Company's listing on The Nasdaq Capital Market. The Company intends to submit the Compliance Plan as soon as practicable. There can be no assurance that the Compliance Plan will be accepted or that if it is, the Company will be able to regain compliance with the minimum stockholder's equity requirement or will otherwise be in compliance with other Nasdaq listing criteria.

08:15 EST Verisk announces integration of LightSpeed solution in Guidewire Marketplace - Verisk has announced the integration of its LightSpeed Small Commercial solution onto Guidewire Marketplace. This integration can help small business insurers automate underwriting workflows and bind new business in seconds. LightSpeed Small Commercial quickly provides insurers with reliable exposure data including the minimum core attributes needed in an automated process as well as insights for more informed decision-making with only the input of basic information. "Insurers face the challenge of delivering quotes at a rapid pace while meeting business growth and profitability targets," said Elizabeth Casas, vice president of commercial lines underwriting at Verisk. "When it comes to small business insurance coverage, it's all about the details. Our LightSpeed Commercial accelerator accurately optimizes in seconds, and now it will enable Guidewire customers to enhance operational efficiency, better serve customers, and drive profitable growth."

08:14 EST General Motors CEO: Stock price 'disappointing for everyone'

08:12 EST GD Culture Group to enhance digital avatar offerings with GPT-4 - GD Culture Group announced its plan to enhance its digital avatar offerings with OpenAI's GPT-4, transforming them into advanced AI agents capable of goal-oriented tasks and interactive communication. By harnessing the power of OpenAI GPT-4, the AI agents will provide users with highly interactive and personalized experiences. Evolved from the Company's existing digital avatars, these AI agents will transcend visually appealing entities to become highly functional and customized AI-powered assistants, each possessing a unique character. Thirty digital avatars will undergo training on the GPT-4 model, equipping them with the cognitive capability to interact in real time, delivering intelligent, contextually relevant, and emotionally resonant responses. The animations and voices of the AI agents will seamlessly synchronize with the language output, creating a lifelike and immersive interaction.

08:11 EST Jeffs' Brands' board to initiate process to provide strategic decision - Jeffs' Brands announced that the Company's board of directors resolved to initiate a process to identify potential strategic transactions, in the field of advanced technologies, with the goal of maximizing shareholder value. Potential strategic transactions to be explored and evaluated during the review process may include additional investments in or acquisitions of innovative companies or a strategic partnership with one or more parties. "We plan on continuing to invest in the development of our brands, particularly the Fort brand, which is continually expanding and delivering remarkable results in the UK. We decided to explore potential strategic transactions, including potential acquisitions of new technologies, aimed at increasing the value we offer to our shareholders," stated Viki Hakmon, CEO of Jeffs' Brands.

08:11 EST Endra Life Sciences issued patent for thermoacoustic probe design by USPTO - Endra Life Sciences announced that the United States Patent and Trademark Office has issued to Endra a new patent, U.S. Patent No. 11828727 titled "Thermoacoustic Probe." The '727 patent relates to a thermoacoustic probe design with an optical transducer and an integrated wedge, which helps to minimize unwanted signals and optimizes radiofrequency signals to the targeted regions of interest. The '727 patent builds upon Endra's U.S. Patent No. 11730374, and is the second of two structural embodiments that Endra is patenting to further protect its core technology.

08:08 EST BioVie announces efficacy data from Phase 3 trial of NE3107 - BioVie announced positive analysis of unblinded, topline efficacy data from its Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer's Disease, AD. Data from evaluable patients show NE3107's treatment advantage compared to placebo may be equal to or greater than the benefit from approved AD monoclonal antibodies. NE3107-treated patients also experienced a 4.66-year advantage in age deceleration vs. placebo as measured by epigenetics/DNA methylation Skin Blood Clock. Key Findings: Patients treated with NE3107 showed improved performance compared to placebo on all cognitive and functional assessments commonly used in the prior approval of amyloid beta-based AD therapies, although the data missed statistically significance due to site exclusions. Placebo-treated patients significantly worsened on virtually all assessments as expected from natural history of the disease. By contrast, NE3107-treated patients experienced a treatment advantage after 6 months that was equal to or greater than results reported from clinical trials for the approved Abeta monoclonal antibody treatments after 18 months. Improvements in Clinical Dementia Rating-Sum of Boxes among NE3107-treated patients appear correlated to changes in tumor necrosis factor alpha, plasma phosphorylated tau, and the ratio of Abeta42 to Abeta40. NE3107 appeared to decrease neuroinflammatory processes that link Neurofilament Light Chain and Glial fibrillary acidic protein, both considered biomarkers of neurodegeneration and cognitive decline. Patients treated with NE3107 saw an average of -5.66 years of age deceleration of the DNA methylation advantage compared to those on placebo. Age deceleration is the difference between the patient's biological age as measured by the Horvath DNA methylation Skin Blood clock less the actual chronological age. NE3107 is believed to be the first drug candidate to demonstrate this impact on DNA methylation and the aging process in a double-blinded, placebo-controlled clinical.

08:08 EST Enveric Biosciences receives notice of allowance from USPTO for EVM301 Series - Enveric Biosciences announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.

08:06 EST Mira announces results from studies of Ketamir-2's oral bioavailability - MIRA Pharmaceuticals announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%. MIRA recently unveiled its revolutionary product, Ketamir-2, which is designed to potentially reshape the landscape of depression treatment. Ketamir-2 lead developer Adam Kaplin, President and Chief Scientific Officer, commented: "Ketamir-2, an innovative analog of Ketamine developed as an oral formulation, signifies a breakthrough for Major Depressive Disorder and MDSI. Tailored for convenient home use, it offers administration ease and aims for fewer side effects, eliminating the need for clinical supervision associated with existing treatments like Spravato." Recent laboratory invitro studies of the CaCO-2 model of human intestinal drug absorption suggested Ketamir-2's superior absorption when taken by mouth compared to Ketamine, with key findings indicating a dramatic 41% net absorption. Given oral Ketamine's previously determined 23% bioavailability when taken by mouth, Ketamir-2's adjusted oral bioavailability based on the CaCO-2 results is predicted to be around 80%1. This bioavailability is more than double that of oral or intranasal absorption of ketamine, promising a potential shift to oral, home administration, granting patients greater autonomy, convenience, and accessibility to effective depression treatment.

08:05 EST Spectaire announces shipment of first commercial units from Columbia Tech - Spectaire Holdings has shipped its first commercial units from manufacturing partner, Columbia Tech, a subsidiary of Coghlin Companies. The outsourcing of manufacturing to Coglin Companies significantly reduces the ramp-up time and capital requirements to initiate the scaled production of AireCore, Spectaire's patented micro-mass-spectrometer. Aligning with an experienced commercialization partner allows Spectaire to focus on delivering units to its customers at scale without investing in the significant overhead of additional facilities, machinery, staff, and other complex infrastructure required to vertically integrate manufacturing. Ahead of the imminent start of the series production and subsequent delivery to customers, Coghlin Companies has already manufactured 40 units for Spectaire and shipped the first units to its customers.

08:04 EST Cocrystal Pharma presents data on CC-42344 at World Vaccine Congress West Coast - Cocrystal Pharma announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, and plans to begin a Phase 1 trial with inhaled CC-42344 as a potential influenza A treatment and prophylaxis in Australia in the first half of 2024. In his presentation, "Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344," Cocrystal President and co-CEO Sam Lee, PhD discussed the potential prevention and therapy of influenza infection using inhaled CC-42344. Dr. Lee commented that CC-42344 exhibits superior antiviral activity compared with oseltamivir and demonstrates a novel mechanism of action with high barrier of resistance. He noted that Cocrystal discovered and developed CC-42344 utilizing the Company's proprietary structure-based drug discovery platform technology, which is proving successful in delivering multiple broad-spectrum antiviral leads for influenza and other viral diseases. "We are excited to accomplish another important milestone with the influenza antiviral CC-42344. Based on our recent preclinical data, CC-42344 exhibits superior lung exposure, a favorable safety profile, and efficacy in influenza-infected human lung epithelia. We also demonstrated highly efficient delivery of inhaled CC-42344 into the lung," he said. "Inhaled CC-42344 could be developed for both therapeutic and prophylactic influenza treatment. We are encouraged by this potential breakthrough influenza treatment option."

08:03 EST Phillips 66 up 4% after CNBC report on activist Elliott building stake

08:02 EST Pasithea Therapeutics announces outcome of pre-IND meeting for PAS-004 - Pasithea Therapeutics announced receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration regarding clinical development plan for PAS-004. The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020. "We are pleased with our PAS-004 Pre-IND meeting minutes which guide us to dose patients who will benefit from treatment. We are excited to begin testing PAS-004 in a first-in-human Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and NF1 mutations including KRAS, NRAS, BRAF and NF1 mutations, who have not responded or recurred following treatment with available therapies as early as the first quarter of 2024 following acceptance of the IND by the FDA", stated Dr. Tiago Reis Marques, CEO.

07:47 EST Ivanhoe Electric, Ma'aden commence JV exploration activites in Saudi Arabia - Ivanhoe Electric announced that exploration activities have commenced in Saudi Arabia by the 50/50-owned joint venture company established between Ivanhoe Electric and Saudi Arabian Mining Company Ma'aden. Ma'aden and Ivanhoe Electric established the Joint Venture to unlock the significant mineral potential in the Kingdom of Saudi Arabia. The Joint Venture has exclusive access to explore approximately 48,500 km2 of underexplored land on the Arabian Shield that Ma'aden will make available to the Joint Venture. The Joint Venture was formally established in July 2023 and was funded with its initial working capital of approximately $66M from Ma'aden's initial $127.1M investment into Ivanhoe Electric common stock. Ma'aden became a 9.9% shareholder in Ivanhoe Electric and subsequently exercised its top-up right in October 2023, investing an additional $20.4less than as part of Ivanhoe Electric's September 2023 follow-on equity offering, maintaining its 9.9% ownership interest. The Joint Venture will have exclusive access to approximately 48,500 km2 of land for exploration in Saudi Arabia. The area comprises a combination of granted exploration licenses and exploration license applications. Ma'aden will make available substitute land for exploration by the Joint Venture if an ELA is not converted to an EL. Ivanhoe Electric is the operator during the exploration phase. Ma'aden will assume operatorship if an economically viable deposit is found and is designated by the Joint Venture for further development.

07:38 EST LQR House repurchases 3.05M shares in ongoing share buyback program - LQR House updates investors on the progress of its Share Buyback Program. On Tuesday, November 21, 2023, amidst record-low stock prices, LQR House strategically acquired 237,700 shares of its common stock at an average cost of $0.04813 per share, adhering to Rule 10b-18 guidelines. Continuing its commitment, on Monday, November 27, 2023, LQR House further acquired 2,000,000 shares of common stock at an average cost of $0.030979 per share, aligning with Rule 10b-18 guidelines. On Tuesday, November 28, 2023, the stock price experienced additional pressure due to market challenges. The Company opted to strategically repurchase shares at historically low values, underscoring its commitment to fulfilling the buyback program. On the same day, LQR House executed the acquisition of 813,022 shares of its common stock at an average cost of $0.0279 per share, in accordance with Rule 10b-18 guidelines.

07:34 EST Amesite announces five-year partnership with Drake State College - Amesite announces a five-year partnership with Drake State Community and Technical College. This collaboration is notable as Drake State is the first community college and the first higher education institution in Alabama to leverage the NAFEO-Amesite Alliance. This partnership represents a strategic move for Drake State, allowing it to extend its educational reach beyond traditional classroom settings. Dr. Ann Marie Sastry, CEO of Amesite, commented on the new partnership. "NAFEO, as the Nation's only advocacy and membership organization for all HBCUs and predominantly Black institutions, has created an efficient and effective way of engaging the most economically significant cohort of institutions that impact workforce diversity in the United States. We are proud to be part of this Alliance, and to work with members like Drake State. This collaboration is an important step for us in Alabama. Our goal is to extend our learning solutions to NAFEO's members. This agreement with Drake State is an important part of our commitment to enhancing education through technology."

07:33 EST Vivos Therapeutics receives FDA clearance for oral device treatment for OSA - Vivos Therapeutics announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration, FDA, for treating severe obstructive sleep apnea, OSA, in adults using the Vivos' removable CARE, Complete Airway Repositioning and/or Expansion, oral appliances. Vivos' CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance. As a result of this FDA clearance, Vivos becomes the first company ever to have approved and bring to market a clear alternative treatment to CPAP or surgical neurostimulation implants for patients with severe OSA. Kirk Huntsman, Chairman and CEO of Vivos, stated, "This achievement is a pivotal milestone for Vivos, and elevates our proven treatment options right into the mainstream of sleep medicine. It is even more important for the millions of severe OSA patients who are desperate for an effective alternative treatment. Before this, severe OSA patients' only realistic treatment options were CPAP, neurostimulation implants or other invasive surgeries. Today, they have what we believe is a far more desirable option that is very affordable and doesn't require surgery or a lifetime of nightly use and intervention."

07:32 EST SAB Biotherapeutics announces commencement of HUMAN Phase 1 trial of SAB-142 - SAB Biotherapeutics announced that the first participants of a HUMAN trial have been dosed in Australia. This Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with T1D. SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D. "This marks an important milestone in our development of SAB-142 as our lead asset enters the clinic," said Alexandra Kropotova, MD, MBA, Executive Vice President and Chief Medical Officer of SAB. "We believe SAB-142 has the potential to be a best-in-class treatment for disease-modification through safe and precise immunomodulation in T1D, based on its validated mechanism of action and safety advantages over rabbit-derived ATG, which has shown significant promise in T1D disease modification. I would also like to extend gratitude on behalf of the entire SAB team to the trial participants and to our Phase 1 partners Avance and Nucleus Network, without whom this trial wouldn't be possible."

07:11 EST Kazia Therapeutics signs LOI to develop and commenrcialize paxalisib - Kazia Therapeutics announced that it has signed a non-binding Letter of Intent, or LOI, with an undisclosed biotechnology company for the license of worldwide rights, other than mainland China, Hong Kong, Macao and Taiwan, to develop and commercialize pharmaceutical product containing paxalisib in an indication outside of cancer. Mutual due diligence has been completed and each company has agreed to move forward to negotiate and use their best efforts to agree to the terms of a definitive agreement. The LOI sets out the proposed terms and preliminary conditions of the agreement as well as a 90-day exclusivity period. The proposed terms include an upfront payment, and potential for clinical and regulatory milestone payments, as well as commercial sales-based royalties and milestones. The companies are currently negotiating the definitive license agreement. There can be no assurance that a definitive license agreement will be executed or that the proposed transaction will be consummated on the terms or timeframe currently contemplated.

07:09 EST 22nd Century appoints Larry Firestone as chairman, CEO - 22nd Century Group announced the appointment of Lawrence Firestone as the Company's Chairman and CEO. Mr. Firestone most recently served as Chief Financial Officer of Oakland Manager, a privately-held purveyor of cannabis with both retail and wholesale market penetration, and as Chairman of FirePower Technology, a privately held manufacturer of ATX power supplies for the IT and instrumentation markets.

07:08 EST uniQure announces FDA clearance of IND application for AMT-191 gene therapy - uniQure announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for AMT-191, the Company's gene therapy candidate for Fabry disease. AMT-191 comprises an AAV5 vector that delivers an alpha-galactosidase A transgene designed to target the liver and produce the deficient GLA protein. The first-in-human Phase I/IIa clinical trial will be conducted in the United States. The multicenter, open-label trial consists of two dose-escalating cohorts of three patients each to assess safety, tolerability, and efficacy of AMT-191 in patients with Fabry disease.

07:05 EST Petco CEO says 'navigate a challenging consumer environment' - "Our third quarter results were below our expectations as we continue to navigate a challenging consumer environment and we are taking swift and decisive action to improve the performance of our business by broadening our appeal with customers and tightly managing costs and capital. This includes the introduction of the category's largest national cat and dog food value brands to meet the needs of all pet parents and deliver incremental profits over time," said Petco CEO Ron Coughlin. "We're confident these actions, combined with continued growth in services, omni-channel capabilities, an industry-leading premium assortment, and dedicated Petco partners will better position us to capture the long-term growth trends in the category and deepen our connection with all pet parents."

07:04 EST enGene names Ryan Daws as CFO - enGene Holdings announced the appointment of Ryan Daws as CFO and Head of Business Development. Daws joins enGene with nearly 25 years of life sciences-focused operational and deal-making experience. Prior to joining enGene, Daws was CFO and Head of Business Development at Obsidian Therapeutics.

07:03 EST EVgo and Meijer expand fast charging partnership through EVgo eXtend - EVgo announced it will install new fast charging stations in the Midwest in an expanded partnership with Meijer, a regional grocery retailer. The new EVgo stations will be built in Ohio and feature up to six stalls at select Meijer locations, equipped with high-power 350kW chargers so that EV drivers can quickly charge and get back on the road. The extended partnership builds upon EVgo and Meijer's existing relationship and will help increase access to public charging for current and future EV drivers in the Midwest. To date, EVgo has deployed 24 charging stalls at six Meijer locations across Michigan and Ohio, including key metropolitan markets, such as Detroit, Cincinnati and Columbus. The extended partnership builds upon EVgo and Meijer's existing relationship and will help increase access to public charging for current and future EV drivers in the Midwest. To date, EVgo has deployed 24 charging stalls at six Meijer locations across Michigan and Ohio, including key metropolitan markets, such as Detroit, Cincinnati and Columbus.

07:03 EST Harrow Health completes transfer of Triesence NDA - Harrow announced the completion of the transfer to Harrow of the new drug application, or NDA, for Triesence 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. In January of 2023, Harrow agreed to acquire the U.S. commercial rights to Triesence. Aside from the transfer of the TRIESENCE NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.

07:02 EST Green Thumb Industries to open RISE Dispensaries in Tampa, Crystal River - RISE Dispensaries announced that it will open two RISE Dispensaries in Florida, with one located in Tampa and the other located in Crystal River, on December 1. These store openings bring the Company's retail footprint to 13 in Florida and 89 nationwide. RISE Dispensary Tampa will host a grand opening celebration on December 16, where profits from the day will be donated to Tu Canna Foundation. RISE Dispensary Crystal River will host a grand opening celebration on December 15, with profits benefitting The Bridge 4 Veterans.

07:01 EST Generation Bio announces strategic reorganization - Generation Bio (GBIO) announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle delivery system for wholly-owned programs in extrahepatic cell types. Generation Bio intends to continue to develop ctLNP for immune cells as part of its collaboration with Moderna and to develop its immune-quiet DNA, or iqDNA, for its lead hemophilia A and other programs. The reorganization actions and financial impacts are as follows: Streamlining R&D to develop wholly-owned ctLNP programs for extrahepatic cell types; Continuing to develop immune cell programs with Moderna (MRNA); Continuing to develop the iqDNA platform for its lead hemophilia A and other programs; Extending cash runway into the second half of 2027; The company will reduce its total workforce by 40%, while preserving core R&D capacity. Several of Generation Bio's leadership team members will also depart as part of the reorganization.

06:51 EST KKR to acquire remaining 37% of Global Atlantic for $2.7B in cash - KKR & Co. and Global Atlantic Financial Group announced a definitive agreement under which KKR will acquire the remaining 37% stake of leading insurance company Global Atlantic, increasing KKR's ownership to 100%. Under the terms of the agreement, KKR will pay Global Atlantic's minority shareholders an amount in cash equal to 1.0x Global Atlantic's book value with certain adjustments. The total cash purchase price is currently estimated to be approximately $2.7B. Global Atlantic management is expected to exchange a majority of its Global Atlantic equity interests for KKR equity. KKR will fund the transaction from its balance sheet, which had $23B of cash and investments as of September 30, 2023. The transaction, which is expected to close in the first quarter of 2024, is subject to customary closing conditions.

06:44 EST GM CEO sees pace of Cruise's expansion 'more deliberate' when operations resume - GEO Mary Barra told shareholders that "What Cruise has accomplished in the eight years since we acquired the company is remarkable. Our priority now is to focus the team on safety, transparency and accountability. We must rebuild trust with regulators at the local, state and federal levels, as well as with the first responders and the communities in which Cruise will operate. This includes making improvements driven by the independent safety and incident reviews that are ongoing. We will share more details on the path forward when we have reviewed the findings and recommendations. We expect the pace of Cruise's expansion to be more deliberate when operations resume, resulting in substantially lower spending in 2024 than in 2023."

06:42 EST GM CEO: 'Disappointed' with Ultium-based EV production in 2023 - CEO Mary Barra told shareholders in a letter that she is "disappointed with our Ultium-based EV production in 2023" due to difficulties with battery module assembly, but says GM has made substantial improvements both to the process and to the organization responsible for this work. In 2024, GM expects significantly higher Ultium EV production and significantly improved EV margins.

06:37 EST PulteGroup plans to reenter the Salt Lake City market - PulteGroup has announced plans to reenter the Salt Lake City market. Beginning with two new construction communities under its Pulte Homes brand, the Company will offer single-family homes and townhomes in Jordanelle Ridge, a new master planned community in Heber. Both communities are expected to grand open in early 2024. Pulte's new Deep Creek at Jordanelle Ridge communities will feature 64 single-family homes and 114 townhomes at buildout. The single-family home community will offer eight floorplans ranging from 2,400 to 2,900+ square feet. There will be four three-story attached home designs from 2,300 to 2400+ square feet for buyers to choose from in the townhome community.

06:36 EST Karuna Therapeutics announces FDA accepted NDA for KarXT - Karuna Therapeutics announced the FDA has accepted its New Drug Application or NDA, for KarXT, or xanomeline-trospium, for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act date of September 26, 2024. The NDA submission is supported by efficacy and long-term safety data from the EMERGENT program, the clinical program evaluating KarXT as a treatment for schizophrenia. The EMERGENT program includes the three completed positive EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating the efficacy and safety of KarXT compared to placebo, and the EMERGENT-4 and EMERGENT-5 trials evaluating the long-term safety of KarXT. In all three placebo-controlled trials, KarXT met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in symptoms of schizophrenia compared to placebo as measured by Positive and Negative Syndrome Scale total score. KarXT was found to be generally well tolerated, with the most common adverse events being cholinergic in nature and mild to moderate in severity. Notably, KarXT was not associated with common side effects of currently available antipsychotics, including weight gain, somnolence, and movement disorders.

06:34 EST General Motors sees FY23 capital spending $11B-$11.5B

06:13 EST Unity to close corporate offices in 14 locations, evaluate real estate footprint - In a regulatory filing on Tuesday, Unity Software said it has committed to a plan to close corporate offices in approximately 14 locations as it evaluates its real estate footprint. The costs and charges associated with the Office Closures, inclusive of potential early termination provisions and sublease income, cannot be reasonably estimated at this time. These costs are expected to be substantially incurred in the fourth quarter of 2023 and the first quarter of 2024. Employees impacted by the Office Closures will have the option to become fully remote, with the exception of specific roles which are location-dependent. On November 25, 2023, as part of the company's previously announced plans to focus on its core businesses, the company amended certain of its agreements with Weta FX Limited, under which the company terminated its obligations to provide certain services to Weta FX and also amended certain intellectual property rights between the parties. The company will recognize deferred revenue and additional consideration in connection with the amendments of approximately $114M, and will expense the recorded cost of a related contract intangible asset of approximately $131M, which will occur in the fourth quarter of 2023.

06:05 EST Beam Global awarded orders from the California Department of General Services - Beam Global announced orders from the California Department of General Services, or DGS, for several of the top State Agencies, adding to Beam's footprint in its leading market in the United States. The EV ARC systems were purchased using the DGS contract #1-22-61-16 which simplifies the state procurement process and ensures the best negotiated pricing. The solar-powered EV ARC EV charging infrastructure products are off-grid, generate and store their own electricity, and are deployed with no electrical work, no construction, and no utility bill, reducing California's costs through avoided construction, electrical upgrades, operational disruptions, and ongoing utility bills.

05:34 EST Elbit Systems awarded $500M Marine Corps contract - Elbit Systems announced that according to the announcement of the U.S. Department of Defense, or DOD, Elbit Systems' U.S. subsidiary, Elbit Systems of America - Night Vision, was awarded an indefinite delivery/ indefinite quantity, or ID/IQ, contract with a maximum ceiling of $500M, for the supply of Squad Binocular Night Vision Goggle, or SBNVG, systems; spare and repair parts; contractor logistics supports and test article refurbishment. Work under the ID/IQ will be performed in Roanoke, Virginia, and is expected to be completed in 2028. Elbit Systems of America received an initial delivery order award under the ID/IQ worth a approximately $127M immediately following contract award. The SBNVG is a lightweight helmet-mounted system that provides superior nighttime viewing in various environments and conditions, improving warfighter situational awareness and performance. The system includes an enhanced battery life and high-performing white phosphor image intensification tubes for improved clarity and depth perception.

05:23 EST Ascendis Pharma enters exclusive license agreement with Teijin for TransCon - Ascendis Pharma announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Under the terms of the agreement, Ascendis will receive an upfront payment of $70M, with additional development and regulatory milestones of up to $175M, transfer pricing and commercial milestones. In addition, Ascendis Pharma is eligible to receive royalties on net sales in Japan, of up to mid-20's percent, varying by product.